Gelonghui January 31 | Xianruida Medical-B (06669.HK) issued an announcement. On January 30, 2024, the company received Peridge, a balloon expansion catheter for peripheral incision from the China National Drug Administrationregistration approval. This product is suitable for the treatment of occlusive lesions of autologous or synthetic arteriovenous fistula tubes used for hemodialysis. PeridgeIt can provide an effective fixed focus point, help open the plaque in a targeted manner, reduce the incidence and severity of elastic contraction of plaques or proliferative endometrial tissue and blood flow restrictive dissection while expanding the lumen, reduce excessive damage to blood vessels, and provide better blood vessel preparation for drug-coated balloon (DCB) treatment. The company will carry out marketing activities in due course in the Chinese market.
先瑞达医疗-B(06669.HK)：PERIDGE注册申请获国家药监局批准
Xianruida Medical-B (06669.HK): PERIDGE registration application approved by the State Drug Administration
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.